Implant Sciences Continues to Expand its Growing EU Market Share with QS-B220s Sold to Austrian Airports

Aug 25, 2015, 09:00 ET from Implant Sciences

WILMINGTON, Mass., Aug. 25, 2015 /PRNewswire/ -- Implant Sciences Corporation (OTCQB: IMSC), a leading manufacturer of explosives trace detection (ETD) and drugs trace detection solutions for homeland security applications, today announced that it has sold 22 of its QS-B220 desktop trace detectors to international airports in Austria, continuing its sales success in the European aviation market.  

With this contract win, international airports in 11 EU countries have selected Implant Sciences' QS-B220 since late April 2015, with orders totaling up to 883 units to such airports.

"When it comes to security, airport operators and security managers are looking for solutions that are easy to own and operate, while providing optimal security for the traveling public. Our systems feature push-button maintenance and an intuitive operating process," stated Dr. Darryl Jones, Implant Sciences' Vice President of Global Sales and Marketing. "The intuitive nature of the QS-B220 allows the security personnel to focus their attention on security, rather than on navigating the interface of the screening equipment. Our low false alarm rate means fewer passengers being unnecessarily inconvenienced which streamlines the checkpoint passenger flow and also provides a superior screening experience for passengers."

"Implant Sciences' cutting-edge ETD technology has a much broader impact than simply having the most sophisticated software, the largest touch-screen, or having the lowest false alarm rate. The impact of the technology is in real terms: fewer passengers stopped unnecessarily, less money spent on consumables, and fewer user errors in operating the system," added Dr. Bill McGann, Implant Sciences' CEO. "Our mission, as the global non-rad ETD experts, is to continue to provide the best technology to meet and exceed the operational needs of our customers."

About the QS-B220 Desktop Explosives Trace Detector

The QS-B220 uses Ion Mobility Spectrometry (IMS) to rapidly detect and identify trace amounts of a wide variety of military, commercial, and homemade explosives. With significantly lower maintenance requirements than competing systems, the QS-B220 can be deployed for a much lower total cost of ownership than other approved products. Featuring a radioactive material-free design, push-button maintenance and diagnostics, and a patented inCal™ internal automatic calibration system, the QS-B220 brings new levels of performance and convenience to desktop trace detection users with unsurpassed ease of use.

About Implant Sciences

Implant Sciences is a leader in developing and manufacturing advanced detection capabilities to counter and eliminate the ever-evolving threats from explosives and drugs. The Company's team of dedicated trace detection experts has developed proprietary technologies used in its commercial products, thousands of which have been sold across 70 countries worldwide. The Company's ETDs have received approvals and certifications from several international regulatory agencies including the TSA in the U.S., ECAC in Europe, CAAC and the Ministry of Public Safety in China, Russia FSB, STAC in France, and the German Ministry of the Interior. It has also received the 2015 GSN Airport/Seaport/Border Security Award for "Best Security Checkpoint".  All Implant Sciences products are recognized as Qualified Anti-Terrorism Technologies by the Department of Homeland Security. For further details on the Company and its products, please visit the Company's website at www.implantsciences.com

Cautionary Note Regarding Forward-Looking Statements

This press release and any statements of employees, representatives and partners of Implant Sciences Corporation (the "Company") related thereto contain or may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995.  Such statements may include, without limitation, statements with respect to the Company's plans, objectives, projections, expectations and intentions and other statements identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar expressions.  Such statements are based on management's current expectations and are subject to significant risks and uncertainties (many of which are beyond the Company's control) that could cause the Company's actual results to differ materially from the forward-looking statements.  Such risks and uncertainties include, but are not limited to, the risks that there is no guaranty that the Transportation Security Administration (TSA) or any other U.S. or foreign government and law enforcement agencies or commercial consumers will purchase any of our explosives detection products or that any new products we may develop will be accepted by the TSA or by such other governments, agencies or consumers; economic, political and other risks associated with international sales and operations could adversely affect our sales; our business is subject to intense competition and rapid technological change, and our ability to generate revenue and profit will depend on our ability to develop and introduce new products; and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including our most recent Forms 10-K, 10-Q and 8-K.  In light of these risks and uncertainties, readers are cautioned that actual results may differ significantly from those described or anticipated in the forward-looking statements.  The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future presentations or otherwise, except as required by applicable law.

Contact:

Implant Sciences Corporation  
Company Contact:  
Robert Liscouski 
978-752-1700 x 116  

SOURCE Implant Sciences



RELATED LINKS

http://www.implantsciences.com